Case Study: a leading genomics-based drug discovery company achieves ~$3M cost reduction with Elucidata’s curated public data platform

a leading genomics-based drug discovery company cuts target discovery time to 6 months and saves ~$3M with Elucidata

The customer, a leading genomics-based drug discovery company, sought to accelerate the identification of new drug targets for immunological diseases and cancer by leveraging publicly available data. They partnered with the vendor Elucidata to utilize its Public OmixAtlas, a repository of highly curated data available on its Polly platform.

Elucidata provided the company with access to its meticulously curated public data on Polly. This solution enabled the client to identify a target for their immunology group in just six months, a process that typically takes two to three years. Elucidata's partnership helped de-risk advancement to Phase II trials, saving an estimated $3 million in costs. It also freed up approximately 2,000 hours annually for the company's R&D and bioinformatics personnel.